Lipid Management Guidelines
Introduction to Lipid Management
- The American Heart Association recommends reducing saturated fat intake to <7% of total calories, limiting dietary cholesterol to <200 mg/day, and minimizing or eliminating alcohol consumption to manage lipid levels, with the goal of reducing cardiovascular risk 1, 2, 3, 4
Dietary Recommendations
- Reduce saturated fat intake to <7% of total calories to manage hypertriglyceridemia 2
- Limit dietary cholesterol to <200 mg/day to reduce cardiovascular risk 2
- Minimize or eliminate alcohol consumption to reduce triglyceride levels, especially for patients with very high triglycerides 3, 4
- Increase physical activity to help manage hypertriglyceridemia and improve lipid profiles 2, 5
- Reduce weight if overweight/obese to improve triglyceride levels and lipid profiles 6, 7
- Limit added sugars to <5% of calories if triglycerides are elevated to reduce cardiovascular risk 3
- For very high triglycerides (>1000 mg/dL), more aggressive dietary fat restriction (<15% of calories) is recommended 3
Pharmacological Treatment
- Prescription omega-3 fatty acids (2-4g daily) are recommended as the preferred add-on therapy for hypertriglyceridemia, with a Class IIb recommendation (Level of Evidence: B) by the American College of Cardiology 2
- Niacin (nicotinic acid) 1-2g daily can reduce triglycerides by 20-40%, but may worsen glycemic control in diabetic patients 6, 2, 8, 7
- Statin intensification (if not at maximum dose) is recommended, particularly if LDL-C or non-HDL-C is also elevated, but with caution due to increased risk of myopathy when combined with fibrates 2
- Fenofibrate is preferred over gemfibrozil due to its efficacy and safety profile, with a recommended dose of 54-160 mg daily, although gemfibrozil can be used at 600 mg twice daily 7, 9
- Statin plus fibrate can be used as second-line treatment, with fenofibrate preferred over gemfibrozil due to lower risk of myopathy 7, 5, 10
- Statin plus nicotinic acid can be used as third-line treatment, but may worsen glycemic control in diabetic patients and should be used with caution 7
Classification and Treatment of Hypertriglyceridemia
- Hypertriglyceridemia can be classified as mild to moderate (150-499 mg/dL), severe (500-999 mg/dL), or very severe (≥1000 mg/dL) 9
- The American Academy of Family Physicians recommends fenofibrate as the first-line pharmacological treatment for severe hypertriglyceridemia (≥500 mg/dL) to reduce the risk of pancreatitis, while for moderate hypertriglyceridemia (150-499 mg/dL), statins remain the first-line therapy with fenofibrate as an adjunctive option 9
- The American Diabetes Association recommends improved glycemic control plus statin as first-line treatment for patients with hyperlipidemia and diabetes 7
Dosage and Administration of Fenofibrate
| Renal Function | Recommended Dose |
|---|---|
| Normal or mild-moderate CKD (CKD stages 1-2) | 96 mg/day |
| Moderate CKD (CKD stage 3) | 48 mg/day |
| Severe CKD (CKD stages 4-5) | Avoid use |
| eGFR 30-59 mL/min per 1.73 m² | ≤54 mg/day |
| eGFR <30 mL/min per 1.73 m² | Discontinue use [11, 12, 13] |
- Fenofibrate is contraindicated in patients with severe renal impairment, active liver disease, preexisting gallbladder disease, and known hypersensitivity to fenofibrate or fenofibric acid 14